Healthpeak Properties Inc (DOC) concluded trading on Thursday at a closing price of $20.93, with 3.92 million shares of worth about $82.14 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 6.95% during that period and on December 12, 2024 the price saw a loss of about -1.60%. Currently the company’s common shares owned by public are about 699.41M shares, out of which, 697.28M shares are available for trading.
Stock saw a price change of -2.61% in past 5 days and over the past one month there was a price change of -3.95%. Year-to-date (YTD), DOC shares are showing a performance of 5.71% which increased to 14.12% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $16.01 but also hit the highest price of $23.26 during that period. The average intraday trading volume for Healthpeak Properties Inc shares is 5.20 million. The stock is currently trading -2.73% below its 20-day simple moving average (SMA20), while that difference is down -4.74% for SMA50 and it goes to 2.27% higher than SMA200.
Healthpeak Properties Inc (NYSE: DOC) currently have 699.41M outstanding shares and institutions hold larger chunk of about 93.75% of that.
The stock has a current market capitalization of $14.93B and its 3Y-monthly beta is at 1.11. PE ratio of stock for trailing 12 months is 44.76, while it has posted earnings per share of $0.47 in the same period. Its PEG reads 8.97 while making debt-to-equity ratio of 1.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DOC, volatility over the week remained 2.42% while standing at 2.18% over the month.
Stock’s fiscal year EPS is expected to drop by -32.54% while it is estimated to decrease by -44.12% in next year. EPS is likely to grow at an annualized rate of 4.99% for next 5-years, compared to annual growth of -24.23% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Deutsche Bank on October 21, 2024 offering a Buy rating for the stock and assigned a target price range of between $20 and $28 to it. On April 26, 2024, Exane BNP Paribas Upgrade their recommendations, while on April 22, 2024, Mizuho Resumed their ratings for the stock with a price target of $22. Stock get a Buy rating from BofA Securities on April 01, 2024.
